SFDA To Release Measures For Drug Reevaluation In 2009
This article was originally published in PharmAsia News
China's State FDA recently disclosed that administrative measures for drug reevaluation are expected to be issued this year. Drug authorities will analyze drug safety based on monitoring reports and research data of drug adverse incidents, then take appropriate measures to control risks. With special focus on TCM injections, the evaluation will reexamine injections' safety, production techniques and procedures. SFDA has compiled a blacklist based on adverse incident reports in recent years; drug manufacturers will have their production licenses revoked once unaccountable adverse incidents are uncovered. In 2008, Chinese patent medicine was the only drug category which decreased in export volume. Experts point out that the only solution for the sector is to upgrade its techniques. (Click here for more - Chinese Language)
You may also be interested in...
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.